Skip to main content

Table 1 Mixed-ANOVA of P300 variables for SCA2 patients, preclinical carriers and healthy controls

From: Insights into cognitive decline in spinocerebellar Ataxia type 2: a P300 event-related brain potential study

ERP Variable SCA2 patients Preclinical carriers Healthy controls Mixed-ANOVA
Group Site Group x Site
Visual Latency       
Cz 462.80 ± 7.40***/¶¶ 421.34 ± 9.06* 384.68 ± 7.08 F = 53.73 F = 0.12 F = 0.10
Pz 463.41 ± 7.40***/¶¶ 420.46 ± 9.92ns 390.54 ± 8.10 p < 0.0001 p > 0.05 p > 0.05
Amplitude       
Cz 9.23 ± 1.12** 11.63 ± 1.41ns 15.28 ± 1.10 F = 14.00 F = 0.20 F = 0.06
Pz 9.03 ± 1.15** 11.44 ± 1.43ns 14.39 ± 1.09 p < 0.0001 p > 0.05 p > 0.05
Auditory Latency  
Cz 437.91 ± 8.88***/¶¶ 380.66 ± 10.88ns 358.05 ± 9.64 F = 41.18 F = 1.09 F = 0.61
Pz 438.21 ± 9.79*** 401.67 ± 11.79* 360.94 ± 10.76 p < 0.0001 p > 0.05 p > 0.05
Amplitude  
Cz 9.47 ± 1.25* 12.63 ± 1.51ns 16.99 ± 1.29 F = 9.47 F = 0.263 F = 0.03
  Pz 9.48 ± 1.11* 11.48 ± 1.33ns 15.50 ± 1.22 p < 0.0001 p > 0.05 p > 0.05
  1. Asterisks denote the statistical differences between SCA2 patients or preclinical carriers and controls (*:p < 0.05; **:p < 0.005; ***:p < 0.0005). Pilcrow denote the statistical differences between SCA2 patients and preclinical carriers (¶¶: p < 0.005)